About

Renal cell carcinoma is kidney cancer that affects the lining of the kidney tubules. The initial stages of the cancer are asymptomatic in most patients and this makes early management of the disease difficult.

Renal cell carcinoma accounts for about 3% of all adult cancers and is also the most common of kidney cancers (90-95%) affecting mostly men, between the ages 50-70 years.

Renal cell carcinoma is commonly seen to affect North Americans and those of Scandinavian ancestry more often than it affects people of Asian or African descent. In the United States, Blacks are more affected than the Whites. Also, the incidence in men is greater than that seen in women. Although the disease is usually detected after age 50, it is seen to occur in young people too who have a family predisposition.

Renal cell carcinoma (RCC) is known for its lack of early symptoms and resistance to treatments such as chemo and radio therapy. However, of late, it has been noticed that these cancers are being detected early and managed through treatments such as thermal ablation, nephron –sparing surgeries, with radical nephrectomy (removal of the kidney and surrounding structures) being the gold standard in treating central and large tumors. Also, targeted therapy is being effectively applied in those with metastatic disease, where the cancer has spread to other parts of the body.

1. People With Kidney Cancer Could be at a Real Risk From NSAIDS

Ibuprofen and other non-steroidal anti-inflammatory medications apart from aspirin could decrease free survival time for patients with metastatic renal cell carcinoma (mRCC)- a type of renal cancer, finds a new study.